Moderna develops combined COVID, Flu vaccine | Daily News

Moderna develops combined COVID, Flu vaccine

Moderna announced it is developing a two-in-one vaccine booster shot that protects against both COVID-19 and the seasonal flu.

The new vaccine, which the company is calling mRNA-1073, combines Moderna’s current COVID vaccine with a flu shot that’s also under development, according to a press release. “Today we are announcing the first step in our novel respiratory vaccine program with the development of a single dose vaccine that combines a booster against COVID-19 and a booster against flu,” CEO Stephane Bancel said in a statement Thursday.

The announcement comes on the heels of Moderna’s highly successful launch of its mRNA-based two-dose Covid vaccine, which was authorized for emergency use by the Food and Drug Administration in December. More than 147 million of the Moderna shots have been administered in the U.S., according to data compiled by the Centers for Disease Control and Prevention.

Messenger RNA, or mRNA, technology has been under development for years, but Moderna’s and Pfizer’s vaccines are the first time mRNA has been cleared for use in humans. The mRNA-based COVID vaccines work by tricking the body to produce a harmless piece of the virus, triggering an immune response. It is said to be easier to produce than traditional vaccines, which generally use a dead or weakened virus to produce an immune response.

Bancel previously said the company hoped to have a booster shot that would combine protection against both viruses.

“What we’re trying to do at Moderna actually is to get a flu vaccine in the clinic this year and then combine our flu vaccine with our COVID vaccine so you only have to get one boost ... every year that would protect you from the variant of concern against COVID and the seasonal flu strain,” Bancel said in April.

Moderna also announced Thursday it is developing a pediatric vaccine, called mRNA-1365, which would combine vaccines for respiratory syncytial virus and human metapneumovirus. (CNBC)

Add new comment